A Catalyst for Modern Diagnostic Technologies From Early Assays to Next-Gen Platforms: The Molecular and Immunoassay Innovations Shaping Modern Testing This eBook explores how innovation across immunoassays and molecular diagnostics is transforming STI testing.
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies From Early Assays to Next-Gen Platforms: The Molecular and Immunoassay Innovations Behind Modern Testing
Meet Our New Ambient-Stable Liquid qPCR Mixes 12-month ambient stability with zero cold-chain dependence Maintain sensitivity, consistency, and performance — from manufacturing to last-mile delivery.
STABILITY AT AMBIENT TEMPERATURE FOR 12 MONTHS
MIX ALONE
MIX WITH PRIMERS & PROBES
Give your customers assays that work anywhere and are reliable, flexible, and freezer-free.
Connect with us:
meridianbioscience.com/lifescience
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies From Early Assays to Next-Gen Platforms: The Molecular and Immunoassay Innovations Behind Modern Testing
4 5 12
Introduction
Beyond the Lab: Building the Future of STI Testing
From Laboratory to Living Room: Who’s Leading in STI Testing Across Laboratory-Based, Point-of-Care, At-Home and Self-Collection Diagnostics?
22
Smarter STI Diagnostics: Multiplexing, Reagent Innovation and Digital Connectivity Case Study: HIV Diagnostics— 40 Years of Innovation from Laboratory to Self-Testing
27
© GEN Publishing • February 2026 Cover & TOC Images: quantic69/Getty Images, dra_schwartz/Getty Images
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Introduction S exually transmitted infections (STIs), often also referred to as sexually transmitted diseases (STDs), remain one of the most preventable and treatable global health challenges. The World Health Organization (WHO) has set an ambitious target: to eliminate key STIs—including syphilis, gonorrhea, chlamydia and trichomoniasis— as public health threats by 2030. Achieving this vision requires not only effective treatment, but also widespread access to accurate, timely and convenient diagnostics. The STI diagnostics market is expanding quickly in response to these needs. Rising infection rates after the COVID-19 pandemic, together with greater awareness of sexual health and advances in molecular technologies, are fueling strong growth. Valued at USD 11.43 billion in 2025, the global STI diagnostics market is projected to reach USD 21.44 billion by 2034, at a compound annual growth rate (CAGR) of 7.38% between 2025 and 2034 (Precedence Research, 2024). This reflects both the scale of the challenge and the demand for more patient-centered, accessible and private testing solutions. A variety of testing modalities are shaping this transformation. In addition to high- throughput laboratory testing, point-of-care (POC) assays are expanding access by delivering rapid results in clinics and community settings. At the same time, at-home kits and self-collection models are gaining momentum, offering unprecedented access while meeting privacy needs that traditional testing has struggled to address. Collectively, these options are breaking down barriers, reducing stigma and supporting earlier detection and treatment—critical steps toward reducing transmission and improving public health outcomes. As accessibility, convenience and privacy become central to diagnostics, the future of STI testing is one of greater empowerment, reach and impact. This eBook explores how innovation and shifting patient expectations are reshaping modern diagnostics—and advancing progress toward global elimination goals.
4 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Beyond the Lab: Building the Future of STI Testing
E very day, more than a million people worldwide contract a curable sexually transmitted infection (STI)—with four infections in particular, chlamydia, gonorrhea, syphilis and trichomoniasis—accounting for the vast majority of cases. Despite being preventable, diagnosable and treatable, these infections persist at alarming levels—a challenge the World Health Organization (WHO) has vowed to eliminate as a public health threat by 2030. Achieving that goal depends on one critical factor: diagnostics. The way we test—how quickly, how accurately and how accessibly—determines whether infections are identified early, treated effectively
and stopped from spreading further.
Traditional sexual health testing requires nurse- or technician-collected samples, a process often avoided due to stigma, cultural sensitivities and privacy concerns. Today, patient expectations for privacy and convenience, along with rising infection rates and greater sexual health awareness, are reshaping the way we test for these infections. In response, diagnostics are modernizing, with expanding modalities ranging from laboratory- based testing to point-of-care (POC), at-home kits and self-collection methods. Each approach plays a critical role in building a comprehensive, patient-centered testing ecosystem.
GENengnews.com | 5
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Syphilis (Treponema pallidum), Gonorrhoea (Neisseria gonorrhoeae), Chlamydia (Chlamydia trachomatis), and Trichomoniasis (Trichomonas vaginalis) INCIDENT CASES OF FOUR CURABLE STIs AMONG ADULTS (15-49 YEARS OLD), By WHO Region, 2020
SOURCE: WHO, 2021
REGION OF THE AMERICAS 74 MILLION [53 MILLION - 104 MILLION]
EUROPEAN REGION 23 MILLION [16 MILLION - 31 MILLION]
WESTERN PACIFIC REGION 86 MILLION [61 MILLION - 117 MILLION]
GLOBAL 374 MILLION [286 MILLION - 481 MILLION]
WHO Regions
SOUTH-EAST ASIA REGION REGION OF THE AMERICAS WESTERN PACIFIC REGION AFRICAN REGION
EASTERN MEDITERRANEAN REGION 36 MILLION [22 MILLION - 56 MILLION]
NOT APPLICABLE EUROPEAN REGION EASTERN MEDITERRANEAN REGION
AFRICAN REGION 96 MILLION [66 MILLION - 134 MILLION]
SOUTH-EAST ASIA REGION 60 MILLION [32 MILLION - 107 MILLION]
Figure 1. Incident Cases of Four Curable STIs Among Adults (15-49 Years Old), By WHO Region, 2020 Image adapted from: World Health Organization. Global Sexually Transmitted Infections Programme. Retrieved from https://www.who.int/ teams/global-hiv-hepatitis-and-stis-programmes/stis/strategic-information
Laboratory-Based Testing: The Cornerstone of Accuracy and Throughput
However, laboratory testing faces inherent challenges. Turnaround times are often long, especially in low-resource or rural settings where samples must be shipped to testing locations. These delays reduce compliance and leave infections untreated, with serious consequences for both individual health and community transmission. Studies of STI clinic populations show that up to 20% of patients with positive chlamydia or gonorrhea tests fail to return within 30 days, and another 30% within two weeks, leaving them infectious and contributing to continued transmission. Untreated chlamydia can
Centralized laboratories remain the backbone of sexually transmitted disease (STD) and sexually transmitted infection (STI) testing, offering high accuracy and broad detection through molecular and serological analysis. These tests often allow for the simultaneous identification of multiple patho- gens, enabling fast determination of the causative organism and detection of potential co-infections.
6 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Delays of even a few weeks can have real consequences. Studies show that patients often remain infectious while awaiting results, and some unknowingly transmit the infection to their partners during that time.
also lead to complications, with up to 30% of cases progressing to pelvic inflammatory disease (PID), each costing over USD 4,000 in future care. 1 Given the high prevalence of asymptomatic infections and the limitations of symptom-based diagnosis, effective STI screening relies on panel- based approaches. 2 Conventional laboratory-based STI testing, in particular multiplex molecular panels that can process multiple pathogens and specimen types simultaneously, offers advantages for large-
scale screening, enabling cost efficiencies and rapid diagnoses. However, new rapid and point-of-care (POC) technologies are gaining traction, promising even quicker, same-day results and increased accessibility. 3 Technology Trends in STI Diagnostics While immunoassays have historically dominated STI diagnostics, holding the largest market share for decades, this shifted in 2024 as molecular diagnostics overtook immunoassays. They now command ~51% of the total market. 4 PCR and isothermal amplification continue to drive this transition, supported by strong adoption in both centralized laboratories and near-patient workflows. Molecular technologies are also expanding faster than immunoassays, growing at approximately 8% CAGR through 2030, 5 while next-generation sequencing (NGS) is projected to grow even faster at 9.29% CAGR 4 —the highest among molecular modalities. Meanwhile, emerging next-generation categories, including microfluidic, sensor-based and hybrid molecular/immuno platforms, are also acceler-
CAGR 8% MOLECULAR
MARKET SHARE BY ASSAY TYPE
51% Molecular
45% Immunoassay
5-6% IMMUNOASSAY
0.7% Other
9.3% NGS ⁕
9% OTHER
Figure 2. STI Testing Market by Assay Type (2025) Molecular diagnostics overtook immunoassays in 2024, now leading with ~51% of the STI diagnostics market and growing at ~8% CAGR to 2030. NGS is expanding even faster at ~9.3% CAGR—the highest among molecular modalities. (Source: Mordor Intelligence, 2025)
GENengnews.com | 7
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
transmission. It also supports timely, personalized counseling that strengthens patient engagement and encourages safer sexual behaviors. 6 As POC technologies advance, innovations such as multiplex detection are delivering a meaningful step forward in patient care. However, POC testing also brings important challenges. Outside controlled laboratory environments, it is more vulnerable to user error, particularly when operators have limited experience with quality control or accreditation requirements. Even when designed for simplicity, POC tests still require laboratory oversight to maintain compliance with quality standards—an added burden for already under-resourced health systems. Cost presents another constraint, as POC testing is typically more expensive per test than centralized laboratory methods. 7 At-Home Testing: Privacy, Convenience and Digital Integration At-home STI testing has quickly become one of the fastest-growing segments of consumer-driven healthcare, emerging in direct response to rising demand for private, convenient screening options.
ating at high growth rates, signaling a broader shift toward decentralized, high-sensitivity and workflow-efficient diagnostic formats. Together, these trends reflect a changing technology landscape: as assay developers seek to combine analytical sensitivity with accessibility, molecular and multimodal platforms are increasingly shaping innovation across both laboratory and near-patient settings. Point-of-Care Testing: Speed and Accessibility in Clinical Settings Point-of-care (POC) testing delivers rapid results—often within minutes to hours—within clinics, urgent care centers and community health settings. Traditional rapid immunochromato- graphic lateral flow assays (LFA) are established tools for infections such as HIV and syphilis, while newer technologies such as microfluidic platforms, rapid molecular assays and multiplex cartridges are expanding POC capabilities. The value of POC testing is its ability to deliver immediate results, enabling same-visit treatment, reducing loss to follow up and helping curb
As testing moves closer to the patient, from centralized labs to self-collection at home, one theme is clear: Convenience must never come at the expense of accuracy.
8 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
COMPARISON OF STI DIAGNOSTIC MODALITIES
PATIENT TURNAROUND TIME
REIMBURSEMENT COST/
MODALITY
KEY BENEFITS
KEY CHALLENGES
EXPERIENCE
Gold-standard accuracy Multiplex panels Immediate treatment Strong for linkage to care
● Delays reduce compliance ● Stigma & access barriers
Clinical setting; requires follow-up Same-visit results and counseling
● ●
1-7 days LABORATORY-BASED
Generally reimbursed
Higher per-test cost; oversight needed
POINT-OF-CARE (POC)
● Quality control ● Training required
● ●
Minutes to hours
● User error ● Limited follow-up Window period issues ● Sample stability/logistics ● Uneven coverage
Accessibility – encourages testing
Private, convenient, stigma-free
●
AT-HOME TESTING
Usually out-of-pocket
Minutes
Private collection and digital results
Variable; some reimbursed, some out-of-pocket
Lab accuracy and at-home convenience
SELF-COLLECTION (LAB-PROCESSED)
●
1-5 days
Figure 3. Comparison of STI Diagnostic Modalities
Most tests use rapid immunoassay formats, enabling individuals to collect a sample, follow simple instructions and receive results within minutes—all without visiting a clinic. Newer assays are beginning to incorporate smartphone apps for guided interpretation, though these digital features are still in the early stages of adoption. The appeal is clear: at-home testing offers speed, discretion and ease. By reducing stigma and logistical barriers, it encourages people who might otherwise delay or avoid testing to take action. This approach is particularly attractive to younger adults, individuals in underserved communities and those navigating busy schedules. Ultimately, the growth of at-home testing reflects a broader shift toward decentralized, patient- centered care. A key challenge for at-home testing is the potential for user error. Issues such as inadequate sample collection, contamination or incorrect interpreta- tion can all affect accuracy. Even small missteps— like reading the result too late—may lead to false negatives, while testing too soon after exposure
can produce unreliable results despite active infection. 8 Although most providers communicate these limitations clearly, accuracy ultimately hinges on consumers following instructions closely and seeking confirmatory testing when needed. Affordability also remains a barrier. Because most at-home kits are sold as over-the-counter products rather than reimbursable services, cost can limit access for individuals with fewer financial resources, reinforcing disparities in testing uptake.
Self-Collection with Laboratory Testing: A Hybrid Model
Self-collection models bridge the gap between laboratory accuracy and at-home convenience. Using mail-in kits, individuals collect specimens such as urine, vaginal swabs or fingerstick blood samples at home, while accredited laboratories perform the testing—often using molecular methods that deliver high sensitivity and specificity. Results are typically returned digitally, supported by clear pathways to follow-up care.
GENengnews.com | 9
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Digital integration further strengthens this model 9 by creating a more connected experience for both patients and health systems. Through secure portals and mobile apps, users can access results quickly alongside educational resources that guide next steps. Many platforms also link directly to telemedicine services for prescriptions, counseling or referrals, while automated reminders support continuity of care by prompting retesting, partner notification and routine screening. For health systems, these digital tools streamline reporting to public health authorities and generate valuable data for surveillance and intervention planning. In this way, self-collection offers a balanced hybrid, combining convenience, privacy and laboratory-grade accuracy, and extending reliable testing options to populations who may avoid in-person care. Yet challenges persist. Maintaining sample stability during transport requires well- engineered kits and dependable logistics, and accuracy can still be affected by improper collection or delays. Cost and reimbursement
also remain barriers: while some insurance plans cover physician-ordered self-collection kits, direct-to-consumer purchases are often paid out of pocket, limiting access for individuals with fewer resources. In some countries, such as Canada, this has contributed to a “two-tiered” system in which private digital STI services enable those who can afford it to bypass long public clinic queues. 10 Ultimately, inconsistent coverage continues to restrict equitable access—particularly for underserved populations who may benefit most from the combination of laboratory precision and at-home convenience. STIs as a Catalyst for Diagnostic Innovation Barriers to STI testing often arise more from human behavior than from technological limita- tions. Stigma, privacy concerns and the need for discreet care have all accelerated the adoption of at-home diagnostics, reinforcing demand for
Webinar
The Evolution of At-Home STI Testing: Advancements in Molecular & Immunoassay Technologies Explore how rising STI rates, shifting patient expectations and post-COVID adoption of at-home care are driving innovation in molecular and immunoassay solutions. Watch this webinar to learn how new chemistries and reagents are enabling the next generation of at-home and self-collection STI assays .
10 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
solutions that prioritize convenience and patient autonomy. In response, diagnostic companies and healthcare providers are reimagining the testing experience through patient-centered design— focusing on accessibility, confidentiality and ease of use. Decentralization continues to expand patient opportunities, with testing now available not only in laboratories but also in pharmacies, community centers and homes. Digital connectivity enhances this ecosystem by linking results to electronic health records, telemedicine services and public health surveillance systems, creating a more seamless continuum of care. References 1. Swain, G. R., et al. (2004). Decision analysis: Point-of-care chla- mydia testing vs. laboratory-based methods. Clinical Medicine & Research, 2 (1), 29-35. https://doi.org/10.3121/cmr.2.1.29 2. Caruso, G., et al. (2021). Current and future trends in the labora- tory diagnosis of sexually transmitted infections. International Journal of Environmental Research and Public Health, 18 (3), 1038. https://doi.org/10.3390/ijerph18031038 3. Karellis, A., et al. (2022). Multiplexed rapid technologies for sexually transmitted infections: A systematic review. The Lancet Microbe, 3 (4), e303-e315. https://doi.org/10.1016/ S2666-5247(21)00191-9 4. Mordor Intelligence. (2025, November 10). STD diag- nostics market size & share analysis—Growth trends and forecast (2025-2030) . Retrieved from https:// www.mordorintelligence.com/industry-reports/ sexually-transmitted-diseases-std-diagnostics-market 5. Grand View Research. (n.d.). Molecular diagnostics for sexually transmitted diseases (STD) market—Industry report 2033 . Retrieved from https://www.grandviewresearch.com/ industry-analysis/molecular-diagnostics-std-market-report 6. Huppert, J., et al. (2010). What is the point? How point-of-care sexually transmitted infection tests can impact infected patients. Point of Care: The Journal of Near-Patient Testing & Technology, 9 (1), 36-46. https://doi.org/10.1097/POC.0b013e3181d2d8cc
Rather than replacing traditional services, at-home and self-collection kits are proving complementary. Research shows that direct- to-consumer testing attracts individuals who might otherwise avoid clinical settings, while others use both self-testing and clinic-based care at different points in their sexual health routines. 11 These innovations also carry broader implications. Advances in self-collection, digital integration and multiplexed POC platforms are increasingly transferable to other infectious disease areas. In this way, progress in STI diagnostics is not only improving sexual health but also shaping the future of diagnostics more broadly. 7. Shaw, J. L. V. (2016). Practical challenges related to point-of-care testing. Practical Laboratory Medicine, 4 , 22-29. https://doi. org/10.1016/j.plabm.2015.12.002 8. Kersh, E. N., et al. (2021). At-home specimen self-collection and self-testing for sexually transmitted infection screening demand accelerated by the COVID-19 pandemic: A review of laboratory implementation issues. Journal of Clinical Microbiology, 59 (11), e02646-20. https://doi.org/10.1128/JCM.02646-20 9. McGuire, M., et al. (2021). HIV self-testing with digital supports as the new paradigm: A systematic review of global evidence (2010-2021). EClinicalMedicine, 39 , 101059. https://doi. org/10.1016/j.eclinm.2021.101059 10. MacKinnon, K. R., et al. (2021). Pay to skip the line: The political economy of digital testing services for HIV and other sexually transmitted infections. Social Science & Medicine, 268 , 113571. https://doi.org/10.1016/j.socscimed.2020.113571 11. Martín-García, D. F., & Santi-Rocca, J. (2024). Direct-to-Consumer Testing: A Game-Changer for STI Control and Public Health? A Critical Review of Advances Since the Onset of the COVID-19 Pandemic. Venereology, 3 (4), 232-245. https://doi.org/10.3390/ venereology3040018
GENengnews.com | 11
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
From Laboratory to Living Room: Who’s Leading in STI Testing Across Laboratory-Based, Point-of-Care, At-Home and Self-Collection Diagnostics? S TI and STD testing are evolving rapidly, driven by advances in technology, digital health and shifting patient expectations.
effectiveness, scalability and ease of deployment across diverse testing environments. However, the market has shifted. Molecular diagnostics have now overtaken immunoassays, capturing ~51% of revenue in 2025 2 as demand grows for higher analytical sensitivity and specificity—particularly for detecting asymptomatic infections. Molecular assays can be more complex to implement outside controlled laboratory settings, but ongoing innovation is rapidly expanding their use across decentralized workflows. Both molecular and immunoassay platforms underpin all four major testing modalities (laboratory-based, point-of-care, at-home and self-collection), each addressing unique barriers to screening, such as reducing turnaround time, improving access or enhancing privacy. Central laboratories remain the foundation for high-throughput testing, while POC platforms enable same-day visit results and treatment. The growth of at-home and mail-in testing has further expanded access for individuals deterred by stigma, cost or geographic isolation. Together, these approaches are creating a more patient-centered diagnostic ecosystem. For assay developers, understanding the strengths and trade-offs of each format is essential to designing next-generation STI testing solutions that balance accuracy, accessibility and ease of use.
Today, options range from laboratory-based assays and clinic-based point-of-care (POC) systems to at-home rapid tests and mail-in self-collection kits that combine convenience with clinical accuracy. Immunoassay technologies continue to play a central role in STI diagnostics, accounting for ~44% of the market in 2024 1 thanks to their cost-
12 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Laboratory-Based Testing: The High-Throughput Cornerstone Laboratory-based testing has long served as the cornerstone of STI diagnostics. Major clinical laboratories and global diagnostics companies dominate this space, leveraging advanced molecular and immunoassay platforms to deliver high-volume, high-accuracy results. Data on total annual STI tests remains limited, as typically only positive results are tracked. 3 However, centralized laboratories, including hospital and reference labs, remain the dominant mode of STI testing, representing approximately 58-62% of the global STI diagnostics market in 2024. 4 Despite advances in decentralized and POC testing, centralized laboratories remain essential, meeting the growing demand for high-throughput, clinically-validated diagnostics. Integrated with electronic medical records (EMRs) and public health databases, they enable efficient test-and- treat workflows and large-scale surveillance.
However, multi-day turnaround times and the need for in-person specimen collection can still limit accessibility and delay results. According to Mordor Intelligence , a small group of global diagnostics companies account for the majority of STI testing worldwide. The five leading firms—Siemens Healthineers, Abbott Laboratories,
OVERVIEW OF MAJOR DEVELOPERS AND TECHNOLOGIES DRIVING THE STI DIAGNOSTICS MARKET
COMPANY
CORE PLATFORM STRENGTHS
ROLE/POSITIONING IN STI TESTING
ROCHE
High-throughput molecular automation (e.g. Cobas systems)
Leader in large centralized labs, multiplex NAAT capability
ABBOTT
Integrated platforms (e.g. Alinity m)
Flexibility across laboratory settings
HOLOGIC
Molecular panels, automated sample processing
Focus on throughput and multiplex STI panels
Rapid modular PCR (e.g. GeneXpert-style) DANAHER (CEPHEID)
Near-patient molecular throughput, fast turnaround
BIOMÉRIEUX
Broad reagent and instrument systems for microbiology and diagnostics
Supports immunoassays and molecular testing in centralized labs
Figure 1. Overview of Major Developers and Technologies Driving the STI Diagnostics Market According to recent market analysis from Mordor Intelligence, the global STI diagnostics sector continues to grow steadily, with five firms collectively accounting for a large share of the global STI testing market. Source: Mordor Intelligence. (n.d.). Sexually transmitted diseases (STD) diagnostics market size & share analysis [Industry report]. Retrieved November 6, 2025, from https://www. mordorintelligence.com/industry-reports/sexually-transmitted-diseases-std-diagnostics-market
GENengnews.com | 13
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Key areas of expertise and differentiation:
• Abbott Laboratories —Offers one of the most extensive portfolios of rapid diagnostic tests, supported by a robust global distribution network • Bio-Rad Laboratories —Specializes in immunoassay and molecular testing with a strong emphasis on research-driven innovation • Danaher (Cepheid) —A leader in molecular POC diagnostics, particularly for HIV and complex STI detection • Hologic —Advances women’s health testing and multiplex assay development for streamlined workflows • OraSure Technologies —Pioneered oral-fluid- based self-testing technologies, improving accessibility and ease of use • QuidelOrtho Corporation —Provides rapid, decentralized testing solutions adaptable to a wide range of clinical settings • Siemens Healthineers —Integrates POC testing within connected diagnostic ecosystems, emphasizing automation and reliability Together, these companies are shaping the future of STI diagnostics through continued innovation, strategic partnerships and expanded global access. While challenges remain—particularly in balancing analytical sensitivity, cost and ease of use—POC technologies are gaining ground as essential tools for same-day diagnosis and treatment. This is especially true where rapid containment and patient engagement are critical.
As STI testing expands beyond the central lab, assay performance must remain consistent across increasingly diverse workflows.
Hologic, Danaher (Cepheid) and Diasorin—offer complementary technological capabilities spanning high-throughput molecular systems, integrated immunoassay platforms and near-patient PCR solutions. 4 Point-of-Care (POC) Testing: Bringing Diagnostics Closer to the Patient POC testing is rapidly reshaping STI diagnostics by delivering results at or near the site of care, bridging the gap between centralized testing and immediate clinical decision-making. Unlike lab-based testing, which requires specimen transport and multi-day turnaround, POC assays provide actionable results within minutes to hours, enabling same-day results and treatment and reducing loss to follow-up. Leading companies in the STI POC testing market include Abbott Laboratories, Bio-Rad Laboratories, Danaher (Cepheid), Hologic, OraSure Technologies, QuidelOrtho Corporation and Siemens Healthineers. 5
14 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
At-Home Testing Kits: Convenience Meets Confidentiality At-home STI testing has evolved from a niche convenience to one of the fastest-growing segments in diagnostics, 6 reflecting a broader movement toward decentralized, user-directed testing. Modern self-contained assays (built on lateral flow and more recently, molecular rapid formats 7 ) allow users to collect samples and perform tests without mailing specimens to a lab, delivering results within minutes. Technology Advancements and Public Health Adoption Growth accelerated during the COVID-19 pandemic, which demonstrated the importance of accessible diagnostics. Rising STI prevalence, 8 improved assay accuracy and user-friendly formats continue to support adoption. At the same time, new technologies such as smartphone-integrated kits, wearable biosensors and AI-enabled interpre- tation tools, are strengthening user confidence by
making self-testing more connected and intuitive. 9
Public health initiatives are also expanding the role of self-testing. The TakeMeHome program— a partnership between BHOC, NASTAD and Emory University—launched in 2020 to increase access to HIV self-testing when traditional services were disrupted. Participation in the program was associated with greater engagement in prevention behaviors, including follow-up STI screening and initiation of HIV preventive medication. 10
Market Landscape, Limitations and Regulatory Momentum
The at-home testing landscape today is shaped by well-established products such as OraQuick® and Insti®, alongside a growing wave of multiplex lateral flow assays capable of detecting multiple infections in a single test. These innovations have expanded what at-home testing can offer, but several limitations still shape how and where at-home tests can be used. Variability in self-collected specimens, the potential for user interpretation errors, regulatory constraints and the ongoing need for confirmatory testing for certain pathogens all limit the scope of fully independent testing. In addition, considerations such as data privacy and supply chain reliability continue to affect user confidence and uptake. At the same time, regulatory momentum is helping to define the next phase of advancement. In March 2025, the US FDA granted clearance for the first home test for chlamydia, gonorrhea and trichomoniasis, marking a pivotal milestone for consumer-accessible STI diagnostics. 11 This approval is expected to accel- erate the development of more digitally-connected,
GENengnews.com | 15
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Although blood-based assays still account for much of the at-home testing market, the rapid uptake of urine, oral fluid and other alternative specimen types is widening the range of tests that can be performed outside clinical settings. The shift toward these more diverse sample types is increasingly shaping the at-home testing market. Developers such as OraSure Technologies, bioLytical Laboratories, Wondfo, LetsGetChecked, BioSure and Everlywell now account for roughly 35% of global market share, 10 reflecting a move toward designs that emphasize ease of use, comfort and accessibility.
user-friendly assays that minimize error, streamline the testing process and make at-home sexual health screening more accessible to a broader population. Shifts in Sample Types and Industry Players Digitally-enabled testing models from companies such as Everlywell and LetsGetChecked are also reshaping how people access sexual health care. By allowing individuals to order kits, collect samples at home and receive certified laboratory results online, these services are helping to normalize home-based screening and reduce traditional barriers to testing.
Self-Collection with Lab Testing: Hybrid Accuracy and Accessibility
Self-collection with lab testing combines the convenience of at-home sampling with the accuracy of centralized laboratory analysis. In this hybrid model, individuals collect at-home specimens such as urine, and vaginal or throat swabs, and mail them to a certified lab for testing on validated molecular or immunoassay platforms. This approach reduces logistical barriers, particularly in remote regions with limited clinic access and transportation challenges. It supports privacy and autonomy without requiring individuals to conduct or manage the test entirely on their own. Adoption of self-sampling accelerated during the COVID-19 pandemic, normalizing its role as a practical and accepted approach to remote testing and specimen collection. For example, England’s National Chlamydia Screening Programme, which began offering online test ordering in 2015, saw the share of its tests initiated through the internet
NEGATIVE YOUR RESULT
Figure 2. Emerging technologies, including smartphone- integrated diagnostic kits, wearable biosensors and AI- enabled analysis tools, are strengthening user confidence and engagement, signaling an ongoing shift toward personalized, data-connected testing solutions. 9
16 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
In the U.K., Preventx, a leading remote testing provider, reportedly processes over 300,000 sexual health tests per month, 14 demonstrating the throughput potential of this model. Other major test manufacturers include BD (Becton, Dickinson and Company), BioSure UK, myLAB Box and LetsGetChecked. Overall, hybrid testing services bridge consumer convenience with clinical-grade accuracy, typically returning results within a few days. 15
increase from around 5% in 2015 to 43% by 2022. 12 In the United States, self-sampling options are now available in 48 of 50 states (all but New York and Rhode Island), with free testing programs offered in 22 states and Washington, D.C. 13 While challenges remain around sample stability, logistics and turnaround times, innovations that improve ease of use, shipping and scalability are expanding adoption of this testing model.
Complementary Modalities for Comprehensive Coverage
Rather than competing, laboratory-based, point-of-care, at-home and self-collection tests increasingly complement one another, creating a comprehensive diagnostic ecosystem. This is particularly valuable in remote or underserved regions and communities where stigma around STIs limits access to testing: • Centralized laboratories provide the depth and reliability required for confirmatory testing and population-level surveillance • Point-of-care (POC) platforms offer immediacy in clinical settings, enabling rapid intervention and outbreak control • At-home and hybrid models extend access and engagement, reaching populations historically underserved by traditional healthcare systems For assay developers, the expanding range of diagnostic formats offers new avenues for innovation. The future lies in integration rather
than replacement, with laboratories supporting complex panels, point-of-care systems addressing urgent or decentralized testing and at-home kits extending access to new populations. Differenti- ation will depend on user-friendly design, digital integration and supply-chain simplicity, enabling tests that are easy to use, ship and store while expanding reach and scalability. At the same time, molecular innovation is increasingly bridging these diagnostic modali- ties. Advances such as isothermal amplification, CRISPR-based detection and emerging multiplex platforms are helping to combine laboratory-grade performance with near-patient accessibility. These innovations are enabling assays that can detect multiple STI targets from a single sample and better reflect real-world patterns of co-infection and clinical presentation. This shift is explored further in Meridian’s article, “Smarter STI Diagnostics: Multiplexing, Reagent Innovation and Digital Connectivity .”
GENengnews.com | 17
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Key Disease Targets in the STI Diagnostics Market While assay type and testing modality shape much of the market, segmenting STI and STD diagnostics by disease state provides clearer insight into where testing volume is concentrated and which infec- tions are driving the strongest growth. The market is defined by several major pathogen targets, each with distinct prevalence patterns, technology preferences and revenue contributions.
• HPV —one of the fastest-growing segments, increasing from USD 2.44 billion in 2025 to USD 3.94 billion by 2030 (10% CAGR), supported by more than 260 commercial tests globally— nearly half manufactured in Asia. 17 • Syphilis —a substantial and steadily expanding market valued at USD 2.29 billion in 2024 and expected to reach USD 4.57 billion by 2034 (6.85% CAGR), dominated by treponemal ELISA and CLIA assays. 19 • HIV —a major contributor valued at USD 1.1 billion in 2024 and projected to reach USD 1.55 billion by 2030 (5% CAGR), with rapid tests driving near-term adoption. 20 • Trichomoniasis —an increasingly recognized but historically under-prioritized STI, with the global trichomoniasis market projected to grow from USD 54.9 million in 2024 to USD 88.3 million by 2030 (8.4% CAGR). 21
Key segments include:
• Chlamydia/Gonorrhea (CT/NG) —the largest segment, driven by high prevalence, routine screening and broad product availability; CT/NG assays remain the highest-volume and among the fastest-growing categories, especially in molecular PCR workflows. 16 • HSV —a smaller but stable segment, estimated at USD 612 million in 2024 and growing at 5.96% CAGR. 18
Brochure
Improve Your Assay Stability: End-to-End Tailored Solutions for qPCR, Isothermal and NGS Enhance assay stability and performance with customized solutions for qPCR, isothermal amplification and NGS. Download the brochure to see how our end-to-end support can streamline your workflow.
18 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
GLOBAL ANNUAL NEW INFECTIONS FOR LEADING STIs
SOURCE: WHO, 2025
80 0 APPROXIMATE NEW INFECTIONS PER YEAR 60 40 20
100
120
140
160
MILLION
1.3 M
Syphilis ( T. pallidum ) Hepatitis B (HBV) HIV
1.5 M
7.1 M
Trichomoniasis ( T. vaginalis ) Chlamydia Gonorrhea ( N. gonorrhoeae ) HPV (Genital) Genital Herpes (HSV-2)
25.6 M
30 M
82 M
129 M
156 M
Figure 3. Global Annual New Infections for Leading STIs Source: World Health Organization. (2025, September 10). Sexually Transmitted Infections (STIs). Retrieved from https://www.who.int/news- room/fact-sheets/detail/sexually-transmitted-infections-(stis)
Together, these targets shape the evolving STI diagnostics landscape, occurring against a backdrop of rising global infection rates. While several STIs continue to show upward incidence trends, expanded screening
access, decentralized testing models and growing public awareness are beginning to help stabilize rates in some regions by enabling earlier detection and reducing the number of undiagnosed cases.
GENengnews.com | 19
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Meridian’s Support for the STI Testing Ecosystem As STI diagnostics continue to expand across laboratory, point-of-care and at-home settings, developers require reagents that maintain performance across diverse workflows and sample
types. Meridian Life Science provides the molecular and immunoassay components that enable this shift—supporting robust, scalable and user-ready diagnostic solutions.
MERIDIAN PORTFOLIO ACROSS DIAGNOSTIC MODALITIES
AT HOME/ SELF-COLLECTION Custom services for conversion to animal free Abs to facilitate global test approvals - Specimen-specific, inhibitor-tolerant master mixes for direct detection
LAB
POINT-OF-CARE
CLIA- and ELISA-validated Abs and Ags qPCR, isothermal and NGS solutions designed for high-throughput testing (dUTP, Lyo-Ready, Liquid Ambient-Stable) Immunoassay blockers, dNTPs and extraction controls
Abs, Ags and HAMA blockers for lateral flow tests Range of isothermal enzymes and mixes (LAMP, NASBA, RPA) Enzymes and mixes to develop cold-chain free assays (glycerol-free, Lyo- Ready, Air-Dryable, Liquid Ambient-Stable)
Assay development services customized to integrate with your diagnostic device
POWERING RELIABILITY AND FLEXIBILITY ACROSS THE DIAGNOSTIC SPECTRUM
20 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
References
1. Grand View Research. STD diagnostics market size & share (2025–2030) [Industry report]. Retrieved November 6, 2025, from https://www.grandviewresearch.com/industry-analysis/ diagnostic-testing-of-stds-market 2. Mordor Intelligence. (2025, November 10). STD diagnostics market size & share analysis—Growth trends and forecast (2025-2030) . Retrieved from https://www.mordorintelligence.com/industry-reports/ sexually-transmitted-diseases-std-diagnostics-market 3. Kersh, E. N., et al. (2021). At-home specimen self-collection and self-testing for sexually transmitted infection screening demand accelerated by the COVID-19 pandemic: A review of laboratory implementation issues. Journal of Clinical Microbiology, 59 . https://doi. org/10.1128/jcm.02646-20 4. Precedence Research. Sexually transmitted diseases (STD) diagnostics market size, share & trends report [Market research report]. Retrieved November 6, 2025, from https://www.precedenceresearch.com/ sexually-transmitted-diseases-diagnostics-market 5. Mordor Intelligence. Sexually transmitted diseases (STD) diagnostics
12. Smith, A. C., et al. (2024). At-home specimen self-collection as an additional testing strategy for chlamydia and gonorrhoea: A systematic literature review and meta-analysis. BMJ Global Health, 9 , e015349. https://doi.org/10.1136/bmjgh-2024-015349 13. Pontes, M. F., et al. (2023). Landscape review of mail-in self-col- lection programs for sexually transmitted infections. Sexually Transmitted Diseases, 50 (6), 336-341. https://doi.org/10.1097/ OLQ.0000000000001787 14. Murphy, L. (2022, April 3). Sheffield sexual health test provider passes four million milestone. The Yorkshire Post. Retrieved November 6, 2025, from https://www.yorkshirepost.co.uk/business/sheffield-sexu- al-health-test-provider-passes-four-million-milestone-3637448 15. Healthline. 7 best at-home STD tests of 2025 that we trust . Retrieved November 6, 2025, from https://www.healthline.com/health/ at-home-std-test#how-they-compare 16. Fortune Business Insights. (2025, November 3). Sexually transmitted diseases (STD) testing market size, share & COVID-19 impact analysis—Report ID FBI101095 . Retrieved from https:// www.fortunebusinessinsights.com/industry-reports/ sexually-transmitted-diseases-testing-market-101095 17. Research and Markets. (2025, November 18). Human Papil- loma Virus (HPV) test and Pap smear/test market research and forecast report 2025-2030: Competitive analysis of market leaders—Hologic, BD, Roche, QIAGEN, and Danaher [Press release]. Globe Newswire. Retrieved from https://www. globenewswire.com/news-release/2025/11/18/3189832/0/en/ Human-Papilloma-Virus-HPV-Test-and-Pap-Smear-Test-Market-Re- search-and-Forecast-Report-2025-2030-Competitive-Analysis-of-Mar- ket-leaders-Hologic-BD-Roche-QIAGEN-and-Danaher.html 18. Research and Markets. (2025, October 8). HSV Testing Market Trends and Forecast Report 2025-2033 | HSV Testing Market to Reach Over USD 1 Billion by 2033 with a CAGR of 5.96% [Press release]. Globe Newswire. Retrieved from https://www.globenewswire.com/ news-release/2025/10/08/3163160/28124/en/HSV-Testing-Market- Trends-and-Forecast-Report-2025-2033-HSV-Testing-Market-to-Reach- Over-USD-1-Billion-by-2033-with-a-CAGR-of-5-96.html 19. Towards Healthcare. (2025, September 12). Syphilis testing market sizing: Syphilis testing market boost by FDA approvals [Insight article]. Retrieved from https://www.towardshealthcare.com/insights/ syphilis-testing-market-sizing 20. Grand View Research. (2025). HIV diagnostics market size & share (2025–2030) [Industry report]. Retrieved from https://www.grand- viewresearch.com/industry-analysis/hiv-diagnostics-market 21. Expert Market Research. (2025). Trichomoniasis market size, share, demand and growth 2034 . Retrieved from https://www.expertmarket- research.com/reports/trichomoniasis-market
market: Global study 2019-2030 . Retrieved November 6, 2025, from https://www.mordorintelligence.com/industry-reports/ sexually-transmitted-diseases-std-diagnostics-market
6. Future Market Insights. At-home testing market trends & growth 2025- 2035 . Retrieved November 6, 2025, from https://www.futuremarketin- sights.com/reports/at-home-testing-market 7. Visby Medical. (2025, March 28). Visby Medical™ receives landmark FDA De Novo authorization for first-ever OTC PCR test for sexual health [Press release]. https://poc.visbymedical.com/news/visby-medical-receives- landmark-fda-de-novo-authorization-for-first-ever-otc-pcr-test-for- sexual-health/ 8. World Health Organization. (2024, May 21). New report flags major increase in sexually transmitted infections, amidst challenges in HIV and hepatitis . https://www.who.int/news/item/21-05-2024-new-report- flags-major-increase-in-sexually-transmitted-infections---amidst-chal- lenges-in-hiv-and-hepatitis 9. Grand View Research. Self-testing market size, share & trends analysis report [Industry report]. Retrieved November 6, 2025, from https://www.grandviewresearch.com/industry-analysis/ self-testing-market-report 10. Global Market Insights. (2025, April). STD self-testing market—By appli- cation, by sample type, by distribution channel: Global forecast 2025-2034 [Market research report]. Retrieved November 6, 2025, from https:// www.gminsights.com/industry-analysis/std-self-testing-market 11. U.S. Food and Drug Administration. (2025, March 28). FDA grants marketing authorization of first home test for chlamydia, gonorrhea and trichomoniasis [Press release]. https://www.fda.gov/news- events/press-announcements/fda-grants-marketing-authoriza- tion-first-home-test-chlamydia-gonorrhea-and-trichomoniasis
GENengnews.com | 21
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Smarter STI Diagnostics: Multiplexing, Reagent Innovation and Digital Connectivity
resilient across a range of environments. Looking ahead, progress in STI diagnostics will be shaped by three key developments: more powerful multiplexing that brings multiple pathogen targets into a single assay, reagent chemistries that remain stable without cold-chain dependence and digital connectivity that links results directly into clinical pathways and patient care. Alongside these shifts, a new wave of molecular platforms is reshaping what STI diagnostics can deliver. Emerging CRISPR-based systems and multimodal assays are beginning to bridge the gap between laboratory-level sensitivity and the accessi- bility needed across decentralized care settings. These technologies expand not only what can be detected, but also how and where testing can occur. Together, they are opening the door to more accessible, high-impact diagnostic solutions worldwide. Unfortunately, conventional screening often requires multiple clinic visits, increasing the likelihood that patients remain untested or are lost to follow-up. Multiplexed technologies, including molecular assays and lateral flow devices capable of detecting multiple pathogens or strains in a single workflow, address this by enabling same-day results within a single visit. Emerging evidence suggests these approaches not only improve feasibility and uptake but also support better patient satisfaction and case detection. 1
T he global scale of the STI and STD burden is unmistakable, and it is pushing the industry toward solutions that deliver real-world impact—faster detection, wider access and reliable performance in real-world conditions. For assay developers, that shift means innovation has to do more than advance technology; it must translate into workflows that are practical, scalable and
Multiplexing Assays: Expanding Detection in a Single Workflow Sexually transmitted infections are often difficult to recognize because they rarely present with clear or consistent symptoms. Many are asymptomatic or disguised by overlapping symptoms, allowing
infections to persist unnoticed and driving STI transmission. The challenge is further complicated by co-infections, where pathogens such as chlamydia, gonorrhea and syphilis circulate together and blur the clinical picture. This silent progression underscores the need for easy, accessible testing.
22 | GENengnews.com
The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Gonorrhea
Chlamydia
Syphilis
Christoph Burgstedt/Getty Images/Alissa Eckert/Science Photo Library/Getty Images
For developers, multiplexing is becoming a central driver of market relevance and adoption by offering: • Stronger clinical utility: Panels that detect multiple pathogens in a single run provide immediate, actionable answers, enabling same- visit treatment decisions—a key differentiator when competing for clinical uptake. • Procurement advantage: Broader panels align with public health and payer priorities for efficiency and cost-effectiveness, making assays more competitive in tenders and reimbursement evaluations. • Future-proofing: Flexible panel architectures allow rapid updates as epidemiology shifts (e.g., rising M. genitalium or emerging resistance markers) without redesigning the entire assay. • Commercial positioning: Multiplex capability supports premium pricing and helps platforms stand out in increasingly crowded STI testing markets.
As multiplexing becomes a growing priority for STI testing, momentum is building around how these capabilities can be delivered at the point of care. Emerging technologies such as cartridge-based real-time PCR (e.g., Cepheid GeneXpert, Abbott ID NOW) and integrated isothermal amplification systems (e.g., LAMP and RPA-based devices 2 ) bring multiplex capabilities closer to decentralized settings. These platforms allow assay developers to maintain laboratory- grade performance in compact, user-friendly formats and expand testing into pharmacies, community clinics and other non-traditional environments. In parallel, advances in lateral flow technology, such as next-generation formats including dot-matrix LFA systems and dual-plat- form approaches like Chembio’s DPP® technology, are enabling higher-order multiplexing, improved analytical sensitivity and more streamlined work- flows at the point of care. The result is a growing toolbox of platforms capable of supporting real-world needs—such as faster turnaround, simplified workflows or the ability to run multiple targets without increasing operational burden.
GENengnews.com | 23
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36Powered by FlippingBook